Key Takeaways: 

• Amplifica is a clinical-stage biopharmaceutical company focused on hair loss. 
• The fresh capital will fuel the next growth phase within its injectable product pipeline.
• Its pipeline targets signaling molecules that reactivate dormant follicles to promote new hair growth.

In 2023, Amplifica reported that scientists at the University of California, Irvine, identified a molecule for treating hair loss.

WHO: Amplifica is a clinical-stage biopharmaceutical company focused on developing novel treatments to address androgenetic alopecia (hair loss), a condition estimated to affect over 50 million men and over 30 million women in the United States alone. The company is taking a nature-inspired scientific approach using a molecular mechanism that regrows natural hair and has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair. Amplifica will initiate product development programs and clinical trials to evaluate the safety and efficacy of its core technology and obtain all applicable regulatory approvals.

WHY: The fresh capital will move the company into its next growth phase, focusing attention on clinical development activities within its injectable hair product pipeline.

IN THEIR OWN WORDS: Frank Fazio, President and CEO of Amplifica, says closing this oversubscribed round “reflects strong investor conviction in the science behind our injectable approach and in the size of the opportunity it addresses. This capital allows us to accelerate our mission to deliver next-generation products to patients confronting the physical and emotional challenges of hair loss.”

“Amplifica has built a proprietary portfolio of...